Search research articles
Contact Us
Filters
Showing results (181-190 of 212) with videos related to
Page
of 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 25, 2020
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Michael A Postow, Susan J Knox, Debra A Goldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2016
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide, Alexander Martens, Jessica C Hassel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2019
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S Phillips, Jennifer Wu, Matthew D Hellmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Georgina V Long, James Larkin, Dirk Schadendorf, et al.
Journal of Translational Medicine
|
September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Science Translational Medicine
|
August 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
Ronglai Shen, Michael A Postow, Matthew Adamow, et al.
Journal of the National Cancer Institute
|
September 11, 2021
Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors
Brian D Gonzalez, Sarah L Eisel, Kristina E Bowles, et al.
The New England Journal of Medicine
|
June 4, 2013
Nivolumab plus ipilimumab in advanced melanoma
Jedd D Wolchok, Harriet Kluger, Margaret K Callahan, et al.
Nature
|
January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
Neuro-Oncology
|
April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 212) with videos related to
Sort By:
Page
of 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 25, 2020
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Michael A Postow, Susan J Knox, Debra A Goldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2016
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide, Alexander Martens, Jessica C Hassel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2019
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S Phillips, Jennifer Wu, Matthew D Hellmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Georgina V Long, James Larkin, Dirk Schadendorf, et al.
Journal of Translational Medicine
|
September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Science Translational Medicine
|
August 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
Ronglai Shen, Michael A Postow, Matthew Adamow, et al.
Journal of the National Cancer Institute
|
September 11, 2021
Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors
Brian D Gonzalez, Sarah L Eisel, Kristina E Bowles, et al.
The New England Journal of Medicine
|
June 4, 2013
Nivolumab plus ipilimumab in advanced melanoma
Jedd D Wolchok, Harriet Kluger, Margaret K Callahan, et al.
Nature
|
January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
Neuro-Oncology
|
April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Page
of 22